**
In a troubling revelation, internal records have unearthed a meeting held last year between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. This gathering, which took place on June 17, 2025, focused on the contentious issue of glyphosate, a widely used herbicide linked to numerous cancer lawsuits. As the Trump administration took steps to bolster Bayer’s position in ongoing litigation, questions arise about the influence of corporate interests on public health policy.
Corporate Influence in Regulatory Decisions
The meeting, which involved key EPA figures, was ostensibly part of routine regulatory dialogues. However, the timing and content of the discussions raise significant ethical concerns. Bayer is embroiled in legal battles with thousands of individuals who allege that their use of glyphosate products, notably Roundup, has resulted in cancer. The lawsuits assert that Bayer neglected to adequately inform consumers about the associated risks, despite a wealth of scientific research suggesting a link between glyphosate and various forms of cancer.
During the meeting, Bayer’s executives were reportedly poised to discuss “litigation” matters, including potential actions before the Supreme Court. They aimed to argue that if the EPA does not mandate a cancer warning for glyphosate, the company cannot be held accountable for failing to provide such a warning. This narrative has been contested in various court rulings, yet the Trump administration has shown a clear inclination to support Bayer’s legal stance.
Actions Following the Meeting
In the wake of the June meeting, the Trump administration’s backing of Bayer intensified. On December 1, 2025, Solicitor General D John Sauer, appointed by the administration, urged the Supreme Court to hear Bayer’s appeal. The Court agreed, scheduling a hearing for April 27, 2026. Moreover, in a striking move on February 18, 2026, the White House invoked the Defense Production Act to safeguard glyphosate production, effectively providing Bayer with a shield against potential liabilities.
The EPA’s support for Bayer is further evidenced by an amicus brief filed by Sauer on March 2, 2026, which explicitly aligned the U.S. government’s position with that of the corporation. Critics have voiced their alarm over the implications of such actions, underscoring a pattern in which corporate interests appear to supersede public health considerations.
Reactions from Advocacy Groups
Environmental advocates have expressed deep concern about the implications of this meeting and the subsequent actions taken by the Trump administration. Nathan Donley, the environmental health science director for the Center for Biological Diversity, emphasised the troubling dynamics at play. “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans,” he argued.
Legal experts and public health advocates have echoed these sentiments. Whitney Di Bona, a consumer safety advocate, noted the stark imbalance in access to regulatory officials. “It’s concerning that the CEO of a major pesticide company can have private meetings with the EPA to talk about limiting the company’s liability,” she stated, questioning whether those affected by glyphosate would receive the same opportunity for dialogue.
The Bigger Picture
The meeting and subsequent administrative actions highlight a growing trend of corporate influence in regulatory processes. Naomi Oreskes, a Harvard professor, pointed out that such high-level discussions between industry leaders and government officials often sideline the voices of ordinary citizens, particularly those directly impacted by the products in question. This dynamic raises significant ethical questions about the integrity of public health policy.
Zen Honeycutt, founder of Moms Across America, reinforced the notion that the system is skewed in favour of corporate interests. “Coercion by chemical companies on our regulatory agencies is nothing new,” she asserted, reflecting on her organisation’s struggles to compel the EPA to act on pesticide restrictions.
Why it Matters
This situation is a stark reminder of the complexities within the intersection of corporate power and public health. As government officials engage with powerful industry leaders, the implications for consumer safety cannot be overstated. The preferential access afforded to corporations raises critical questions about the prioritisation of profits over the wellbeing of the public. In a time when environmental and health crises are increasingly pressing, ensuring that regulatory bodies remain independent and accountable becomes imperative. The dialogue surrounding glyphosate serves as a pivotal case study in the ongoing battle for transparency and integrity in environmental governance.
